PURPOSE: N-(2-mercaptoethyl)1,3-diaminopropane (WR-1065), is the active metabolite of amifostine, a broad spectrum cytoprotective agent used in conjunction with both chemo- and radiotherapy of certain cancers. This report describes for the first time an oral formulation of WR-1065 and follows on from our earlier report of a similar oral formulation of amifostine. MATERIALS AND METHODS: The nanoparticles of WR-1065 were prepared by spray drying technique using poly lactide-co-glycolide (PLGA) as the polymer matrix. Radioprotection was determined by measuring reductions in radiation-induced: (i) 30-day survival; (ii) bone marrow suppression; and (iii) intestinal injury following 9 Gray (Gy) whole body gamma irradiation in mice. All treatments were given 1 hour pre-irradiation and WR-1065 was tested at the dose of 500 mg/kg. RESULTS: The WR-1065/PLGA nanoparticles were smooth and spherical with the average diameter of 206 nm and contained 21.7% (w/w) WR-1065. While irradiation markedly reduced 30-day survival in non-treated control mice, and caused significant bone marrow suppression and intestinal injury in surviving mice, oral administration of WR-1065/PLGA nanoparticles resulted in significant radioprotection as evidenced by a marked reduction in all three of the above mentioned parameters of radiation injury. CONCLUSIONS: These findings clearly demonstrate the feasibility of developing an effective oral formulation of WR-1065 as a radioprotective agent.
PURPOSE:N-(2-mercaptoethyl)1,3-diaminopropane (WR-1065), is the active metabolite of amifostine, a broad spectrum cytoprotective agent used in conjunction with both chemo- and radiotherapy of certain cancers. This report describes for the first time an oral formulation of WR-1065 and follows on from our earlier report of a similar oral formulation of amifostine. MATERIALS AND METHODS: The nanoparticles of WR-1065 were prepared by spray drying technique using poly lactide-co-glycolide (PLGA) as the polymer matrix. Radioprotection was determined by measuring reductions in radiation-induced: (i) 30-day survival; (ii) bone marrow suppression; and (iii) intestinal injury following 9 Gray (Gy) whole body gamma irradiation in mice. All treatments were given 1 hour pre-irradiation and WR-1065 was tested at the dose of 500 mg/kg. RESULTS: The WR-1065/PLGA nanoparticles were smooth and spherical with the average diameter of 206 nm and contained 21.7% (w/w) WR-1065. While irradiation markedly reduced 30-day survival in non-treated control mice, and caused significant bone marrow suppression and intestinal injury in surviving mice, oral administration of WR-1065/PLGA nanoparticles resulted in significant radioprotection as evidenced by a marked reduction in all three of the above mentioned parameters of radiation injury. CONCLUSIONS: These findings clearly demonstrate the feasibility of developing an effective oral formulation of WR-1065 as a radioprotective agent.
Authors: Lurong Zhang; Weimin Sun; Jianjun Wang; Mei Zhang; Shanmin Yang; Yeping Tian; Sadasivan Vidyasagar; Louis A Peña; Kunzhong Zhang; Yongbing Cao; Liangjie Yin; Wei Wang; Lei Zhang; Katherine L Schaefer; Lawrence J Saubermann; Steven G Swarts; Bruce M Fenton; Peter C Keng; Paul Okunieff Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-01 Impact factor: 7.038
Authors: Jessica M Molkentine; Tara N Fujimoto; Thomas D Horvath; Aaron J Grossberg; Carolina J Garcia Garcia; Amit Deorukhkar; Marimar de la Cruz Bonilla; Daniel Lin; Errol L G Samuel; Wai Kin Chan; Philip L Lorenzi; Helen Piwnica-Worms; Robert Dantzer; James M Tour; Kathryn A Mason; Cullen M Taniguchi Journal: Sci Rep Date: 2019-02-13 Impact factor: 4.379